For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 361 | 1,346* | 1,769 | 1,879 |
| General and administrative | 1,642 | 1,237* | 1,596 | 1,018 |
| Total operating expenses | 2,003 | 2,583 | 3,365 | 2,897 |
| Loss from operations | -2,003 | -2,583* | -3,365 | -2,897 |
| Change in fair value of warrant liability | - | 0* | 0 | 0 |
| Interest income | 5 | 5* | 6 | 5 |
| Net loss | -1,998 | -2,579* | -3,359 | -2,892 |
| Deemed dividend on series b warrants | - | 0* | - | - |
| Net loss available to common stockholders | - | -2,579 | - | - |
| Basic EPS | -1.61 | 0.569 | -1.28 | -1.31 |
| Diluted EPS | -1.61 | 0.569 | -1.28 | -1.31 |
| Basic Average Shares | 1,241,001 | -4,532,151 | 2,621,498 | 2,205,139 |
| Diluted Average Shares | 1,241,001 | -4,532,151 | 2,621,498 | 2,205,139 |